The Role of PIK3CA Mutations as A Predictor of Outcomes and A Therapeutic Target Grace M. WangBen Ho Park ReviewPaper 23 September 2010 Pages: 167 - 173
Anti-Angiogenic Strategies in Breast Cancer: An Update Adrienne B. GropperErica L. Mayer ReviewPaper 24 September 2010 Pages: 174 - 181
Metabolic Syndrome, Insulin Resistance, and Inflammation in Breast Cancer: Impact on Prognosis and Adjuvant Interventions Pamela J. Goodwin ReviewPaper 23 September 2010 Pages: 182 - 189
PARP Inhibitors for the Treatment and Prevention of Breast Cancer Shaveta VinayakJames M. Ford ReviewPaper 26 September 2010 Pages: 190 - 197
Targeting Epigenetic Modifications for the Treatment and Prevention of Breast Cancer Bhuvaneswari RamaswamyJoseph A. Sparano ReviewPaper 08 October 2010 Pages: 198 - 207
Strategies to Incorporate Translational Research Science into Clinical Trials in Breast Cancer Debora FumagalliChristine DesmedtChristos Sotiriou ReviewPaper 22 October 2010 Pages: 208 - 213
Targeting the Immune System as a Therapeutic Strategy for Patients with Breast Cancer Teresa Gilewski ReviewPaper 19 October 2010 Pages: 214 - 221
Bisphosphonates in Breast Cancer: From Metastasis to Prevention Joaquim Bosch-BarreraSofia D. Merajver ReviewPaper 26 September 2010 Pages: 222 - 230